Dynavax Revenue

Pharmaceutical Manufacturing • Düsseldorf, North Rhine-Westphalia, Germany • 51-100 Employees

Dynavax revenue & valuation

Annual revenue	$7,101,065
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$22,800,000
Total funding	No funding

Key Contacts at Dynavax

Magda Peckruhn

Senior Director Hr

Tolleri Lorenzo

Senior Director Business Development

Karl Luyten

Director Plant Engineering

Eric Frings

Vice President & Site Head Managing Director

Kai Scholz

Executive Director & Head Of Manufacturing

Melanie Knospe

Associate Director Qa Systems

Patrick Gillessen

Associate Director Qa Validation & Release

Robert Bonsels

Associate Director Process Engineering

Arne Sandrock

Director Of Engineering

Andreas Richter

Head Of Quality And Managing Director At Dynavax Gmbh Düsseldorf

Company overview

Headquarters	Eichsfelder Str.11, Duesseldorf, 40595, DE
Phone number	+49200000098
Website	dynavax.com
NAICS	3254
Employees	51-100
Socials

Dynavax Email Formats

Dynavax uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@dynavax.com), used 98.5% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@dynavax.com	98.5%
{first initial}{last name}	jdoe@dynavax.com	1.5%

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. Dynavax GmbH is the European affiliate of Dynavax Technologies Corporation USA, located in Düsseldorf, Germany. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals. Dynavax GmbH is led by an experienced management team with demonstrated expertise in vaccine and biopharmaceutical product development and manufacturing. Our success is seen through the production of recombinant proteins of our licensed technology platform. Dynavax GmbH Employee Benefits - Jobrad - Recognition Awards - Fitness Membership - Flexible Working Hours - Free Membership for Corporate Benefits - Employee Breakfasts - Christmas and Summer Parties - Free Parking

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Dynavax has 49 employees across 8 departments.

Departments

Number of employees

Funding Data

Dynavax has never raised funding before.

Frequently asked questions

Dynavax is located in Düsseldorf, North Rhine-Westphalia, DE.

You can reach Dynavax at +49200000098.

Dynavax generates an estimated annual revenue of $7,101,065. This revenue figure reflects the company's market position and business performance in its industry.

Dynavax has an estimated valuation of $22,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Dynavax has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.